Progression of Precancerous Cervical Lesion Predicted by p16 Protein Immunohistochemistry in Rajavithi Hospital
(ندگان)پدیدآور
Charoonwatana, TipnareeBoonlikit, SathoneYanaranop, Marutنوع مدرک
TextResearch Articles
زبان مدرک
Englishچکیده
Objective: To assess the association of p16 immunohistochemical (IHC) staining in cervical squamous intraepitheliallesions (SIL) and progression of cervical intraepithelial neoplasia (CIN) 1 to CIN2+ or recurrence of CIN2+. Materialand Methods: A retrospective cohort study of women with newly diagnosed SIL from colposcopy-directed biopsy atRajavithi Hospital, 2013-2017. Pathologic specimens were reviewed and submitted to p16-IHC staining. Adjusted hazardratios (HR) of disease-free interval (DFI) and 95% confidence intervals (CI) were carried out using the Cox proportionalhazard regression model. Results: A total of 187 women was recruited, 91 cases of positive p16-IHC staining and 96cases of negative staining. With the median follow-up time of 22 months, women with positive p16-IHC had significantlylower 1-year DFI than those with negative p16-IHC (86.8% vs. 96.6%, p = 0.006). Women with CIN 1 had 22.6% ofpositive p16-IHC, while those with CIN2-3 had 86.7%. From multivariate analysis, the positive p16-IHC and age >35 years were the significant prognostic factors of progression/recurrent CIN2+ (adjusted HR 5.33, 95%CI 1.77-16.01,p = 0.003; and adjusted HR 5.80, 95%CI 1.34-25.08, p = 0.019, respectively). From subgroup analysis, the positivep16-IHC was the significant prognostic factor in women with initial CIN1 (HR 5.29, 95%CI 1.18-23.76, p = 0.030), butwas not associated with prognosis in women with initial CIN 2-3 (HR 2.13, 95%CI 0.28-16.38, p = 0.468). Conclusion:Overexpression of p16 protein has the prognostic significance of SIL. Using p16-IHC may help stratify patients aslow-risk and high-risk groups to progression/recurrence CIN2+.
کلید واژگان
p16 protein immunohistochemistrycervical intraepithelial neoplasia
precancerous cervical lesion
Gynaecological oncology
شماره نشریه
6تاریخ نشر
2019-06-011398-03-11
ناشر
West Asia Organization for Cancer Prevention (WAOCP)سازمان پدید آورنده
Department of Obstetrics and Gynecology, Rajavithi Hospital, Bangkok, Thailand.Department of Obstetrics and Gynecology, Rajavithi Hospital, Bangkok, Thailand.
Department of Obstetrics and Gynecology, Rajavithi Hospital, Bangkok, Thailand.
شاپا
1513-73682476-762X




